News

Type 2 Diabetes Screening Beneficial, Regardless of Treatment Intensity

Publish date: September 22, 2010

 

Dr. Griffin said he has received lecture fees from GSK, Unilever, Eli Lilly, and MSD. His attendance at the 2008 EASD meeting was paid by Eli Lilly. Dr. Herman stated that he had nothing to disclose.

Pages

Recommended Reading

Can CV Monitoring Warnings or REMS Restrictions Save Meridia?
MDedge Internal Medicine
Vitamin D Deficiency Linked to Risk of Heart Failure Death
MDedge Internal Medicine
Elevated BNP Predicts Risk in General Population
MDedge Internal Medicine
Serotonin a Possible Marker for Decompensated Heart Failure
MDedge Internal Medicine
FDA Panel Splits on Whether to Take Sibutramine Off the Market
MDedge Internal Medicine
FDA Approves Use of Cardiac Resynchronization Therapy Defibrillators for Heart Failure
MDedge Internal Medicine
FDA Reviewing Actos's Safety
MDedge Internal Medicine
Metabolic Syndrome Threatens Heart Health Regardless of Diabetes Status
MDedge Internal Medicine
FDA Panel Votes to Approve Dabigatran for Reduction of Stroke Risk
MDedge Internal Medicine
Self-Management Techniques Fail to Improve Heart Failure
MDedge Internal Medicine